Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

BACKGROUND: Acute myeloid leukemia (AML) remains a devastating disease with a 5-year survival rate of less than 30%. AML treatment has undergone significant changes in recent years, incorporating novel targeted therapies along with improvements in allogeneic bone marrow transplantation techniques. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, May, Stark, Michal, Ofran, Yishai, Assaraf, Yehuda G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809753/
https://www.ncbi.nlm.nih.gov/pubmed/33446189
http://dx.doi.org/10.1186/s12935-021-01746-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809753/
https://www.ncbi.nlm.nih.gov/pubmed/33446189
http://dx.doi.org/10.1186/s12935-021-01746-w

Ejemplares similares